Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States.
作者信息
Usón Junior Pedro Luiz Serrano, Ahn Daniel, Sonbol Mohamad Bassam, Bekaii-Saab Tanios, Borad Mitesh J
机构信息
Hospital Israelita Albert Einstein, São Paulo, Brazil.
Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA.
出版信息
Hepatobiliary Surg Nutr. 2020 Aug;9(4):501-504. doi: 10.21037/hbsn.2019.11.20.
Abstract
摘要
相似文献
1
Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States.美国肝胆癌免疫治疗应用的前景
Hepatobiliary Surg Nutr. 2020 Aug;9(4):501-504. doi: 10.21037/hbsn.2019.11.20.
2
Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.美国肝胆癌免疫疗法的应用：不同社会经济地位患者之间的差异
Hepatobiliary Surg Nutr. 2020 Feb;9(1):13-24. doi: 10.21037/hbsn.2019.07.01.
3
The State of Immunotherapy in Hepatobiliary Cancers.免疫疗法在肝胆肿瘤中的应用现状
Cells. 2021 Aug 15;10(8):2096. doi: 10.3390/cells10082096.
4
Novel immunotherapy strategies for hepatobiliary cancers.新型免疫疗法治疗肝胆肿瘤。
Immunotherapy. 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024.
5
The upward trend in the immunotherapy utilization for hepatobiliary cancers.肝胆癌免疫治疗的使用呈上升趋势。
Hepatobiliary Surg Nutr. 2021 Oct;10(5):692-695. doi: 10.21037/hbsn-21-342.
6
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.肝胆胰肿瘤的癌症疫苗和免疫治疗方法。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2931-2952. doi: 10.1080/21645515.2017.1359362. Epub 2017 Nov 7.
7
Treating Hepatobiliary Cancer: The Immunologic Approach.治疗肝胆癌：免疫治疗方法。
Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3.
8
T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy.T 细胞亚群作为肝胆癌的潜在生物标志物，以及免疫治疗方案作为治疗策略的选择。
J Natl Compr Canc Netw. 2022 Feb;20(2):203-214. doi: 10.6004/jnccn.2021.7097.
9
The microbiome and hepatobiliary-pancreatic cancers.微生物组与肝胆胰癌症
Cancer Lett. 2017 Aug 28;402:9-15. doi: 10.1016/j.canlet.2017.05.001. Epub 2017 May 17.
10
Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.老年美国成年人自身免疫性疾病与肝胆癌风险之间的关联。
Int J Cancer. 2019 Feb 15;144(4):707-717. doi: 10.1002/ijc.31835. Epub 2018 Nov 8.
本文引用的文献
1
Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.美国肝胆癌免疫疗法的应用：不同社会经济地位患者之间的差异
Hepatobiliary Surg Nutr. 2020 Feb;9(1):13-24. doi: 10.21037/hbsn.2019.07.01.
2
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
3
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
4
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
5
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
6
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.顺铂联合吉西他滨与吉西他滨治疗胆管癌。
N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.
7
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件